HCC cell lines (MHCC-97H, LM3, HepG2, and Hep3B) and human normal liver cells (QSG-7701) were respectively cultured in dulbecco’s minimum essential medium (DMEM) or Roswell Park Memorial Institute (RPMI)-1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 1% streptomycin/penicillin and 10% FBS (Fetal Bovine Serum) (Thermo Fisher Scientific). The cell cultures were grown at 37 ℃ with a continuous supply of 5% carbon dioxide (CO2). The HCC cell lines were provided by the Cell Bank at UCAS (Chinese Academy of Sciences, China). The QSG-7701 was obtained from Beyotime (Shanghai, China). Lenvatinib (Beyotime, SF5346-10 mM) concentration was progressively increased weekly up to 10 µM. After 30 weeks of treatment, HepG2 Lenvatinib-resistant (LR) cell lines (with mixed cell populations, not from a single clone) were obtained.
Lenvatinib
Manufactured by Beyotime
Sourced in China
Lenvatinib is a laboratory reagent used for research purposes. It is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in angiogenesis and tumor growth. The core function of Lenvatinib is to inhibit these kinases, which can be useful in various research applications.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using lenvatinib
1
Establishing Lenvatinib-Resistant HCC Cell Lines
2
CDDP and Kinase Inhibitor Treatments
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CDDP extracts were purchased from Tasly Pharmaceutical Group Co. Ltd. (Tianjin, China, 27 mg/package, batch number 20210103) and dissolved using dimethyl sulfoxide (DMSO) (Sigma–Aldrich, Munich, Germany) to make different concentrations. In previous research, the chemical profile of CDDP had been fully investigated using HPLC [17 (link)]. The final DMSO concentration was ≤ 0.5% weight/volume (w/v) in all treatment groups. The VEGF receptor kinase inhibitor (VRI) lenvatinib, PI3K inhibitor LY294002 (LY) and AKT inhibitor VIII (AKTi) were obtained from Beyotime Technology (Shanghai, China).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!